Lumosa Therapeutics Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	35.83	39.15	56.92	26.64	17.36
Revenue Growth (YoY)	-8.49%	-31.21%	113.63%	53.45%	-19.81%
Cost of Revenue	13.96	21.44	15.44	12.08	7.47
Gross Profit	21.87	17.71	41.48	14.56	9.89
Selling, General & Admin	51.01	51.8	47.8	40.02	34.12
Research & Development	304.37	322.86	369.3	280.46	406.05
Operating Expenses	355.36	374.83	417.26	320.48	440.17
Operating Income	-333.49	-357.12	-375.78	-305.92	-430.28
Interest Expense	-0.2	-0.19	-0.05	-0.15	-0.26
Interest & Investment Income	20.16	13.43	18.49	5.84	3.46
Currency Exchange Gain (Loss)	0.29	6.87	-4.21	11.02	-3.73
Other Non Operating Income (Expenses)	6.91	2.41	2.76	2.11	1.67
EBT Excluding Unusual Items	-306.32	-334.6	-358.79	-287.1	-429.14
Impairment of Goodwill	-	-	-	-	-78.49
Gain (Loss) on Sale of Investments	-40.29	-102.24	119.08	-217.4	627.61
Asset Writedown	-	-	-10.37	-	-24.03
Other Unusual Items	-	-	-	0.05	-
Pretax Income	-346.62	-436.84	-250.09	-504.45	95.95
Income Tax Expense	-	-	0.25	0.04	-
Earnings From Continuing Operations	-346.62	-436.84	-250.33	-504.48	95.95
Minority Interest in Earnings	6.08	12.05	12.29	9.82	-
Net Income	-340.54	-424.78	-238.04	-494.66	95.95
Net Income to Common	-340.54	-424.78	-238.04	-494.66	95.95
Shares Outstanding (Basic)	166	163	162	162	151
Shares Outstanding (Diluted)	166	163	162	162	151
Shares Change (YoY)	1.68%	0.64%	0.03%	7.61%	24.92%
EPS (Basic)	-2.05	-2.60	-1.47	-3.05	0.64
EPS (Diluted)	-2.05	-2.60	-1.47	-3.05	0.64
Free Cash Flow	-361.16	-296.78	-342.53	-302.74	-452.69
Free Cash Flow Per Share	-2.17	-1.81	-2.11	-1.86	-3.00
Gross Margin	61.05%	45.24%	72.88%	54.65%	56.96%
Operating Margin	-930.73%	-912.09%	-660.23%	-1148.26%	-2478.27%
Profit Margin	-950.41%	-1084.91%	-418.23%	-1856.70%	552.62%
Free Cash Flow Margin	-1007.96%	-757.97%	-601.82%	-1136.33%	-2607.34%
EBITDA	-329.17	-353.03	-356.93	-288.66	-403.81
D&A For EBITDA	4.32	4.09	18.85	17.26	26.47
EBIT	-333.49	-357.12	-375.78	-305.92	-430.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.